Talaris Therapeutics to Present at American Society of Hematology (ASH) Annual Meeting

BOSTON, Mass., and LOUISVILLE, Ky., Dec. 6, 2019 – Talaris Therapeutics, Inc., a privately held biotechnology company developing transformative cell therapies that have the potential to eliminate the burden of chronic immunosuppression for organ transplant recipients, announced that founder Dr. Suzanne Ildstad will present a poster at the American Society of Hematology annual meeting, taking place December 7-10, 2019, in Orlando, Fla.

The presentation will address the potential of Talaris’ one-time cell therapy, FCR001, to induce immune tolerance in both matched related and unrelated recipients of living donor kidney transplants (LDKT). In Talaris’ Phase 2 trial of FCR001, 26 of 37 LDKT recipients were able to be weaned off all immunosuppressive treatments; subsequently, every tolerized patient has remained off all chronic immunosuppression, with median follow-up since transplant of approximately five years and longest follow-up of almost 10 years. The degree of HLA mismatch, spanning 0/6 to 6/6 between the donor and the recipient, did not affect either the safety or the efficacy of the therapy. Read the full abstract here.

The following are specific details regarding Talaris’ poster presentation:

Title:               Hematopoietic Mononuclear Cell Transplant with Minimal GVHD in up to Completely Mismatched Unrelated Recipients

Number:        3243

Session:        704. Immunotherapies: Poster II

Date:              Sunday, December 8, 2019

Time:              6:00 p.m. – 8:00 p.m. ET

Location:       Hall B, Orange County Convention Center, Orlando, Fla.

About FCR001

FCR001 is an investigational, allogeneic cell therapy developed by Talaris Therapeutics to induce or restore patients’ immune tolerance. FCR001 builds on over 30 years of research by the company’s founder, Dr. Suzanne Ildstad, into the means by which durable immune tolerance can be induced in a patient who receives a transplanted organ or can be restored in patients with certain immune-mediated or blood disorders. FCR001 has received both Orphan Drug Designation and Regenerative Medicine Advanced Therapy (RMAT) designation from the U.S. Food and Drug Administration. A Phase 3 trial of FCR001 in living donor kidney transplant recipients is now enrolling patients. More information about the FREEDOM-1 trial can be found at: https://www.clinicaltrials.gov/ct2/show/NCT03995901

About Talaris Therapeutics

Talaris Therapeutics, Inc. is a late-clinical stage biotechnology company that is developing transformative cell therapies with the potential to eliminate the burden of chronic immunosuppression for organ transplant recipients as well as induce durable remissions in patients with severe auto-immune and immune-mediated disorders. Talaris was founded on technology discovered and developed by Dr. Suzanne Ildstad and operates its own cell processing facility in Louisville, KY. Talaris is backed by leading life sciences investors Blackstone Life Sciences, Longitude Capital and Qiming Venture Partners USA and maintains corporate offices in Boston, MA and Louisville, KY. www.TalarisTx.com.

Media Contact

Lisa Raffensperger
Ten Bridge Communications
lisa@tenbridgecommunications.com
(617) 903-8783